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Abstract
Introduction: The availability of raltegravir plus atazanavir provides an alternative antiretroviral strategy that may
be equally efficacious and less toxic than those currently recommended in HIV treatment guidelines. In fact, this
new combination antiretroviral therapy attracts the attention of the scientific community because both drugs have
a good safety profile coupled with potent antiviral activity, and their combined use would avert nucleoside- and
ritonavir-related toxicities.
Case presentation: We describe the case of a 47-year-old, Caucasian woman treated for HIV-1 infection who
developed Buffalo Hump during antiretroviral therapy, including raltegravir and unboosted atazanavir. Clinical
evaluation and an ultrasonography scan of the cervical region showed a new progressive increase of
lipohypertrophy and the results of DEXA confirmed these data. In our patient the worsening of the Buffalo Hump
cannot be attributed to hypercortisolism; insulin-resistance, diabetes, dyslipidemia, hyperlactatemia and metabolic
syndrome were not present. Moreover, she was not in therapy with antiretroviral drugs that are described as the
cause of Buffalo Hump; on the other hand she developed this side effect three months after the switch of the
antiretroviral therapy to raltegravir plus unboosted atazanavir.
Conclusion: Current data indicate that the etiology of HIV-associated Buffalo Hump remains elusive but is likely
multifactorial; a possible contributing cause, but not the main cause, could be exposure to antiretroviral drugs. To
the best of our knowledge, this is the first report on development of Buffalo Hump in the course of antiretroviral
therapy, including the use of these drugs. On the basis of our data we can formulate the hypothesis of a
pharmacological pathogenesis that underlies the development of this case of Buffalo Hump in the absence of
other risk factors.
Introduction
Antiretroviral (ARV) treatment guidelines currently
recommend ARV regimens containing a Nucleos(t)ide
Reverse Transcriptase Inhibitors (N(t)RTIs) based back-
bone with a Non Nucleoside Reverse Transcriptase Inhi-
bitor (NNRTI) or ritonavir boosted Protease Inhibitor
(PI/r). However, significant toxicity has been associated
with N(t)RTI(s) and PI/r containing regimens. Recent
data presented by Gupta et al. show that the combina-
tion of raltegravir (RAL) plus unboosted atazanavir
(ATV) may be an alternative effective ARV regimen
demonstrating good virologic and immunologic
response. Furthermore, the combination is well tolerated
and has a low incidence of adverse effects [1]. Moreover,
side effects reported by Zhu et al. during a study in
healthy subjects were generally “mild-to moderate” in
i n t e n s i t y .C o m m o ns i d ee f f e c t ss e e nw h e nb o t hd r u g s
were taken were jaundice and headache [2]. Ripamonti
et al. evidenced that after five to seven months of ther-
apy based on RAL plus ATV no patients discontinued
* Correspondence: giancarlo.ceccarelli@uniroma1.it
1Department of Infectious Diseases and Public Health, “Sapienza” University,
Rome, Italy
Full list of author information is available at the end of the article
Ceccarelli et al. Journal of Medical Case Reports 2011, 5:70
http://www.jmedicalcasereports.com/content/5/1/70 JOURNAL OF MEDICAL
CASE REPORTS
© 2011 Ceccarelli et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.treatment due to drugs used in therapy, adverse events,
and no one had a grade 3 or 4 lab toxicity [3]. For these
reasons this combination of antiretroviral therapy based
on RAL plus ATV attracts the attention of the scientific
community because both drugs have a good safety pro-
file coupled with potent antiviral activity, and their com-
bined use would avert nucleoside- and ritonavir-related
toxicities.
Case presentation
We describe the case of a 47-year-old, Caucasian
woman treated for HIV-1 infection, who developed buf-
falo hump during antiretroviral therapy consisting of
RAL and unboosted ATV. She was diagnosed with HIV
disease in February 1999: the CD4+ cell count was 214/
mm3 (11%) and the HIV viral load was 253,200 copies/
ml at that stage. An initial highly active antiretroviral
therapy (HAART) regimen consisted of zidovudine,
lamivudine and indinavir. After 18 months, the therapy
was changed to stavudine, lamivudine and nevirapine
because of an episode of acute renal colic. Our patient
attended outpatient clinics on a regular basis, and was
found to have a good immunological and virological
response to HAART. By July 2004, she presented with a
progressive peripheral fat loss; facial lipoatrophy was
apparent but not severe. For these reasons the HAART
combination was changed (November 2004), and stavu-
dine was replaced by a nucleotide analogue tenofovir.
The CD4+ count was 599/mm3 (16%) and the HIV viral
load was < 50 copies/ml at the change of the antiretro-
viral medications. She was on nevirapine and lamivudine
plus tenofovir for five years with a good immune-virolo-
gical response. We observed neither other fat accumula-
tion nor fat loss and no significant metabolic disorders
after the switch. Body Mass Index (BMI), glucose, cho-
lesterol, triglyceride, plasma cortisol and insulin concen-
trations were normal.
In November 2009 the patient presented with a HIV
viral load of 1551 copies/ml; a subsequent test of resis-
tance showed the presence of K65R, K103S, M184V,
and G190A. Because she refused therapies with an
increased risk of metabolic alterations, the antiviral
treatment was changed to RAL 400 mg with unboosted
ATV 200 mg twice daily.
Three months later, it was noted that she developed a
new progressive increase of lipohypertrophy of the
dorso-cervical region of the neck. There was no loca-
lized accumulation of fat in her abdomen and in the
submental region of her neck. The hump in the back of
her neck was causing neck pain, headaches off and on
and sleep apnea. It was causing her discomfort and
affecting the motion of her neck. An ultrasonography
scan of the cervical region reported a large amount of
subcutaneous fat around the posterior aspect of the
neck (Figure 1). The results of DEXA confirmed these
data. Fasting lipid profile showed a total Cholesterol of
170 mg/dl, HDL-Cholesterol 42 mg/dl and Triglycerides
148 mg/dl. Fasting plasma glucose and response to a
glucose tolerance test were normal. Her waist circumfer-
ence was 80 cm and her BMI was 21. Moreover, there
were no significant changes noted in diet, physical activ-
ity, and body weight. Thyroid hormones, plasma insulin,
cortisol, estradiol, progesterone, prolactin, luteinizing
and folliclestimulating hormone concentrations were
normal. Her CD4-lymphocyte count was 844/mm3
(20%) and HIV viral load was < 50 copies/ml.
In the next three months she developed a massive
lipohypertrophy of the dorso-cervical region of her neck.
For this reason the plastic surgery staff proposed surgi-
cal removal of the BH due to discomfort, localized pain
and the progressive increase of lipohypertrophy of the
dorso-cervical region of the neck. The patient refused
this option and six months later we observed a stabiliza-
tion of the subcutaneous fat of the cervical region.
Discussion
Buffalo Hump is commonly reported in adults with HIV-
associated lipodystrophy. Accumulation of fat over the
dorso-cervical spine is reported in 2% to 13% of HIV
infected patients with a higher prevalence (6 to 13%) in
those showing any other feature of the lipodystrophy syn-
drome [4]. The pathogenesis underlying this aspect of
lipodystrophic syndrome is poorly understood. Guallar
et al. reported that Buffalo Hump adipose tissue shows
specific disturbances in gene expression with respect to
subcutaneous fat from HIV-1-infected/HAART-treated
Figure 1 Ultrasonography scan of the cervical region. The scan
evidenced a massive lipohypertrophy of the dorso-cervical region of
the neck (the maximum diameter identified by focusing up and
down through the planes of the section was 7.45 cm). The area of
fat accumulation was extended over the entire cervical region.
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associated with other physical features of the lipodystro-
phy phenotype and suggest that hyperinsulinemia, insulin
resistance, obesity, and hypercortisolism, are important
components of this phenotype [6-9]. The close relation-
ship between Buffalo Hump and glycaemic parameters
suggests patients with Buffalo Hump are at higher risk for
diabetes and metabolic syndrome. In fact, biochemically,
patients with Buffalo Hump tend to have or develop signs
or symptoms of metabolic syndrome. Mallon et al.
reported that patients with Buffalo Hump had higher BMI
and more total limb and abdominal fat than patients with-
out Buffalo Hump. Current data indicate that a possible
contributing cause, but not the main one, could be expo-
sure to antiretroviral drugs: risk factors for Buffalo Hump
are longer duration of use of protease inhibitors and
longer duration of use of zidovudine [10]. Palacios et al.
showed that Buffalo Hump was associated with treatment
with saquinavir, indinavir, efavirenz, tenofovir and stavu-
dine. Moreover, time of exposure to stavudine and fat loss,
one of stavudine’s major side-effects, were associated with
Buffalo Hump [11]. Previous reports, however, indicated
that the appearance of buffalo hump could not be asso-
ciated with any specific component of HAART regimes
and that it is associated with specific disturbances in gene
expression of adipose tissue [4,5].
We report the development of the Buffalo Hump can-
not be attributed to hypercortisolism; insulin resistance,
diabetes, dyslipidemia, hyperlactatemia and metabolic
syndrome were not present. Moreover, there were no
significant changes noted in our patient’sd i e t ,b o d y
weight and BMI. Her lifestyle was normal and she fol-
lowed a regular exercise program.
At the moment she is not in therapy with antiretro-
viral drugs that are described as the cause of Buffalo
Hump; on the other hand she developed this side effect
three months after the switch of the antiretroviral ther-
apy to RAL plus unboosted ATV. A caveat of this report
is that she had a history of exposure to antiretroviral
drugs (Zidovudine, Stavudine, Indinavir) associated with
the development of Buffalo Hump. This condition may
have predisposed the patient to develop the disorder
and could constitute a background that contributes to
the final appearance of buffalo hump after raltegravir
plus atazanavir treatment. Current data indicate that the
etiology of HIV-associated Buffalo Hump remains elu-
sive but is likely multifactorial and includes, metabolic
disorders, genetic factors, receipt of ART and HIV infec-
tion itself [12].
Conclusions
The availability of RAL and ATV provides an alternative
ARV strategy that may be equally efficacious and less
toxic than those currently recommended in HIV
treatment guidelines. However, there are few data in the
literature available to date regarding such a combina-
tion. There are no publications today that describe a
relationship between RAL and unboosted ATV therapy
and the occurrence of Buffalo Hump. This is the first
report on the development of Buffalo Hump in the
course of antiretroviral therapy including these drugs:
on the basis of our data we can formulate the hypothesis
of a pharmacological pathogenesis that underlies the
development of this case of Buffalo Hump in absence of
other risk factors. More investigation is required to
determine if RAL plus unboosted ATV is a safe alterna-
tive to RTV boosted PI based ARV strategies and if
there are significant side effects related to this ARV
treatment.
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